Abstract
In the present study, we have investigated the protective effect of a heterologous prime-boost strategy with priming plasmid DNA followed by recombinant adenovirus, both expressing BmAMA1, against Babesia microti infection. Four groups consisting of 3 hamsters per group were immunized with pBmAMA1/Ad5BmAMA1, pNull/Ad5BmAMA1, pBmAMA1/Ad5Null and pNull/Ad5Null, followed by challenge infection with B. microti. Our results showed that hamsters immunized with plasmid and adenovirus expressing BmAMA1 developed a robust IgG and IgG2a antibody response against BmAMA1, suggesting the DNA vaccine or viral vector vaccine tend to induce a Th1-biased response. Compared to the control hamsters, the hamsters vaccinated either with the prime-boost strategy or one of the two “vaccines” exhibited no significant protection against B. microti challenge. Although a slight difference in terms of parasitemia and hematocrit values at days 14–16 post challenge infection was observed, no other statistical difference was detected. Our results indicate that the prime-boost vaccination strategy of injection of plasmid and adenovirus expressing BmAMA1 is not efficient in protecting against B. microti infection.
Article PDF
Similar content being viewed by others
References
Mountford, A.P., Fisher, A., Wilson, R.A., 1994. The profile of lgCl and IgC2a antibody responses in mice exposed to Schistosoma mansoni. Parasite Immunology, 16, 521–527
Anderson, R.J., Schneider, J., 2007. Plasmid DNA and viral vectorbased vaccines for the treatment of cancer. Vaccine 25, 24–34. DOI: 10.1016/j.vaccine.2007.05.030
Caetano, B.C., Bruña-romero, O., Fux, B., Mendes, E.A., Penido M.L.O., Gazzinelli, R.T., 2006. Vaccination with Replication-Deficient Recombinant Adenoviruses Encoding the Main Surface Antigens of Toxoplasma gondii Induces Immune Response and Protection Against Infection in Mice. Human Gene Therapy 17, 415–426
Campos-Neto, A., 2005. What about Th1/Th2 in cutaneous leishmaniasis vaccine discovery? Brazilian Journal of Medical and Biological Research, 38, 979–984
Dunachie, S.J., Hill A.V.S., 2003. Review Prime-boost strategies for malaria vaccine development. The Journal of Experimental Biology, 206, 3771–3779. DOI: 10.1242/jeb.00642
Dutta, S., Sullivan, J.S., Grady, K.K., Haynes, J.D., Komisar, J., Adrian H., et al., 2009. High Antibody Titer against Apical Membrane Antigen-1 Is Required to Protect against Malaria in the Aotus Model PLoS One 4, e8138. DOI: 10.1371/journal.pone.0008138
Harvey, K.L., Yap, A., Gilson, P.R., Cowman, A.F., Crabb, B.S., 2014. Insights and controversies into the role of the key apicomplexan invasion ligand, Apical Membrane Antigen 1. International Journal for Parasitology, 44, 853–857. DOI:10.1016/j.ijpara.2014.08.001
Hildebrandt, A., Hunfeld, K.P., Baier, M., Krumbholz, A., Sachse, S., Lorenzen, T., et al., 2007. First confirmed autochthonous case of human Babesia microti infection in Europe. European Journal of Clinical Microbiology & Infectious Diseases. 26, 595–601. DOI:10.1007/s10096-007-0333-1
Homer, M.J., Aguilar-Delfin, I., Telford, S.R., Krause, P.J., Persing D.H., 2000. Babesiosis. Clinical Microbiology Reviews, 13, 451–69. DOI: 10.1128/CMR.13.3.451-469.2000.
Igarashi, I., Suzuki, R., Waki, S., Tagawa Y.-I., Seng, S., Tum, S., et al., 1999. Roles of CD4+ T Cells and Gamma Interferon in Protective Immunity against Babesia microti Infection in Mice. Infection and Immunity. 67, 4143–4148
Indresh, K.S., Margaret, A.L., 2013. Gene Vaccines. Ann. Annals of Internal Medicine, 138, 550–559
Kochan, G., Gherardi, M.M., Esteban, M., Pe, E., 2006. MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis. Microbes and Infection, 8, 810–822. DOI: 10.1016/j.micinf.2005.10.004
Krause, P.J., Gewurz, B.E., Hill, D., Marty, F.M., Vannier, E., Foppa I.M., et al., 2008. Persistent and relapsing babesiosis in immunocompromised patients. Clinical Infectious Diseases, 46, 370–376. DOI: 10.1086/525852
Kumar, S., Gubernot, D.M., Nakhasi, H.L., Mied, P.A., Asher, D.M., Epstein, J.S., 2009. Transfusion-transmitted babesiosis in the United States: Summary of a workshop. Transfusion, 49, 2759–2771. DOI: 10.1111/j.1537-2995.2009.02429.x
Liu, M.A., Ulmer, J.B., 2005. Human Clinical Trials of Plasmid DNA Vaccines. Advances in Genetics. 55, 25–40. DOI: 10.1016/S0065-2660(05)55002-8
Marathe A, Tripathi J, Handa V, Date V. 2005. Human babesiosis–A case report. Indian Journal of Medical Microbiology, 23, 267–269
Moitra, P., Zheng, H., Anantharaman, V., Banerjee, R., Takeda, K., Kozakai, Y., et al. 2015. Expression, purification, and biological characterization of Babesia microti apical membrane antigen 1. Infection and Immunity, 83, 3890–3901. DOI: 10.1128/IAI.00168-15
Ramshaw, I.A., Ramsay, A.J., 2000. The prime-boost strategy: exciting prospects for improved vaccination. Immunology Today, 21
Reyes-Sandoval, A., John, T., Todryk, S.M., 2007. Viral vector vaccines make memory T cells against malaria. Immunology 121, 158–165. DOI: 10.1111/j.1365-2567.2006.02552.x
Stowers, A.W., Kennedy, M.C., Keegan, B.P., Saul, A., Long, C.A., Miller, L.H., Mmun I.N.I., 2002. Vaccination of Monkeys with Recombinant Plasmodium falciparum Apical Membrane Antigen 1 Confers Protection against Blood-Stage Malaria. Infection and Immunity 86, 6961–6967. DOI: 10.1128/IAI.70.12.6961
Takeda, A., Igarashi, H., Nakamura, H., Kano, M., Iida, A., Hirata, T., et al., 2003. Protective Efficacy of an AIDS Vaccine, a Single DNA Priming Followed by a Single Booster with a Recombinant Replication-Defective Sendai Virus Vector, in a Macaque AIDS Model. Journal of Virology 92, 9710–9715. DOI: 10.1128/JVI.77.17.9710
Vannier, E., Gewurz, B.E., Krause, P.J., 2008. Human Babesiosis. Infectious Disease Clinics of North America 22. DOI: 10.1016/j.idc.2008.03.010
Wang, G., Efstratiou, A., Franck, P., Moumouni, A., Liu, M., 2017. Experimental Parasitology Expression of truncated Babesia microti apical membrane protein 1 and rhoptry neck protein 2 and evaluation of their protective efficacy. Experimental Parasitology. 172, 5–11. DOI: 10.1016/j.exppara.2016.11.001
Woodland, D.L., 2004. Jump-starting the immune system: prime–boosting comes of age. Trends in Immunology, 25. DOI: 10.1016/j.it.2003.11.009
Yu, L., Yamagishi, J., Zhang, S., Jin, C., Oluga, G., 2012. Parasitology International Protective effect of a prime-boost strategy with plasmid DNA followed by recombinant adenovirus expressing TgAMA1 as vaccines against Toxoplasma gondii infection in mice. Parasitology International, 61, 481–486. DOI: 10.1016/j.parint.2012.04.001
Zhang, G., Huang, X., Boldbaatar, D., Battur, B., 2010. Construction of Neospora caninum stably expressing TgSAG1 and evaluation of its protective effects against Toxoplasma gondii infection in mice. Vaccine, 28, 7243–7247. DOI: 10.1016/j.vaccine.2010.08.096
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wang, G., Yu, L., Efstratiou, A. et al. Evaluation of the protective effect of a prime-boost strategy with plasmid DNA followed by recombinant adenovirus expressing BmAMA1 as vaccines against Babesia microti infection in hamster. Acta Parasit. 63, 368–374 (2018). https://doi.org/10.1515/ap-2018-0042
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1515/ap-2018-0042